The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.
The organization is teaming up with CereMark Pharma to conduct research on improving outcomes in soldiers and athletes with neurodegenerative conditions.
Most EP clinical study data are from men, Anne Kroman, DO, explained in an interview. This is a significant problem, she said, because heart rhythm issues look quite different in women.
A conference on neurology is described by reporters as "shambolic," offering only bare bones presentations and accommodations. And the number of these events may be on the rise.
Even grafts that represent the current gold standard for bypass surgeries are associated with high failure rates, researchers noted. They think these 3D-printed blood vessels could provide considerable value.
New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.
![Researchers have developed artificial blood vessels that could be as strong and durable as the real things, publishing their work in Advanced Materials Technologies.[1] The group hopes its work could go on to make a significant impact in care for heart bypass patients.](/sites/default/files/styles/240x220/public/2024-07/screenshot_2024-07-25_at_2.38.35_pm.png.webp?itok=Kv-BN0d2)
